Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

81.28 +0.89 (+1.11%)

Delayed Quote Updated: 10:09 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

May 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗

May 07, 2026

This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Mirum (MIRM) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗

May 06, 2026

Via Chartmill

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 06, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

May 04, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

May 03, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

April 29, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook ↗

February 25, 2026

Via Chartmill

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

April 27, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗

April 19, 2026

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 13, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗

April 13, 2026

This small biotech could grow much larger with some good news from its pipeline.

Via The Motley Fool

Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗

April 01, 2026

Mirum (MIRM) Q2 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Mirum Pharma (MIRM) Earnings Call Transcript ↗

April 01, 2026

Mirum Pharma (MIRM) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗

April 01, 2026

Mirum (MIRM) Q1 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Intellectual Property

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

Via The Motley Fool

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

March 16, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗

March 15, 2026

HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience

March 05, 2026

NEW YORK — The euphoric "small-cap comeback" that defined the opening weeks of 2026 came to a grinding halt on Thursday. The Russell 2000 index, the primary barometer for American small-cap health,...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

March 05, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum (MIRM) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Mirum (MIRM) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

February 25, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles ↗

February 25, 2026

Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision...

Via The Motley Fool

Topics Artificial Intelligence

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

February 23, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

February 18, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.